{"id":3701,"date":"2022-05-05T05:43:22","date_gmt":"2022-05-05T05:43:22","guid":{"rendered":"https:\/\/aceoncology.org\/?p=3701"},"modified":"2022-05-05T05:43:23","modified_gmt":"2022-05-05T05:43:23","slug":"tislelizumab-plus-chemo-regimen-in-npc","status":"publish","type":"post","link":"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/","title":{"rendered":"PD-1\u6291\u5236\u5242\u8054\u5408\u5316\u7597\u83b7\u5f97\u665a\u671f\u9f3b\u54bd\u764c\u4e00\u7ebf\u6cbb\u7597\u8bc1\u636e"},"content":{"rendered":"\n<p>\u9f3b\u54bd\u764c\uff08Nasopharyngeal cancer\uff0cNPC\uff09\u5728\u897f\u65b9\u56fd\u5bb6\u662f\u4e00\u79cd\u7f55\u89c1\u75c5\uff0c\u800c\u5728\u4e1c\u5357\u4e9a\u53d1\u75c5\u7387\u8f83\u9ad8\u3002\u5927\u591a\u6570\u60a3\u8005\u786e\u8bca\u65f6\u5df2\u5904\u4e8e\u665a\u671f\uff0c\u901a\u5e38\u91c7\u7528\u542b\u94c2\u5316\u7597\uff08\u5982\u987a\u94c2\u8054\u5408\u5409\u897f\u4ed6\u6ee8\u65b9\u6848\uff09\u8fdb\u884c\u6cbb\u7597\u3002\u7136\u800c\uff0c\u5c3d\u7ba1\u63a5\u53d7\u4e86\u6cbb\u7597\uff0c\u4f46\u9884\u540e\u4ecd\u7136\u8f83\u5dee\uff0c\u610f\u5473\u7740\u9700\u8981\u66f4\u6709\u6548\u7684\u6cbb\u7597\u65b9\u6848\u6ee1\u8db3\u4e34\u5e8a\u9700\u6c42\u3002\u5e78\u8fd0\u7684\u662f\uff0c\u8fd1\u671f\uff0c\u5728\u5316\u7597\u7684\u57fa\u7840\u4e0a\u8054\u5408\u514d\u75ab\u7597\u6cd5\u5728\u8fd9\u4e2a\u75be\u75c5\u7a7a\u95f4\u663e\u793a\u51fa\u4e86\u53ef\u559c\u7684\u7597\u6548\u3002<\/p>\n\n\n\n<p>\u57284\u6708\u7684ASCO\u5168\u4f53\u4f1a\u8bae\u4e0a\uff0c\u4e2d\u5c71\u5927\u5b66\u80bf\u7624\u9632\u6cbb\u4e2d\u5fc3\u5f20\u529b\u6559\u6388\u4ecb\u7ecd\u4e86\u968f\u673a\u3001\u53cc\u76f2\u3001III\u671fRATIONALE-309\u7814\u7a76\u7684<a href=\"https:\/\/meetings.asco.org\/asco-plenary-series\/14566?presentation=206232#206232\">\u6700\u65b0\u7ed3\u679c<\/a>\u3002\u8fd9\u9879\u5728\u4e2d\u56fd\u8fdb\u884c\u7684\u7814\u7a76\u8bc4\u4ef7\u4e86PD-1\u6291\u5236\u5242\u66ff\u96f7\u5229\u73e0\u5355\u6297\u8054\u5408\u6807\u51c6\u5409\u897f\u4ed6\u6ee8-\u987a\u94c2\u5316\u7597\u4f5c\u4e3a\u665a\u671fNPC\u60a3\u8005\u4e00\u7ebf\u6cbb\u7597\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\u5171\u6709263\u4f8b\u590d\u53d1\/\u8f6c\u79fb\u6027\uff08R\/M\uff09NPC\u521d\u6cbb\u60a3\u8005\u968f\u673a\u63a5\u53d7\u66ff\u96f7\u5229\u73e0\u5355\u6297\u6216\u5b89\u6170\u5242\u8054\u5408\u5409\u897f\u4ed6\u6ee8-\u987a\u94c2\u65b9\u6848\u6cbb\u7597\uff08\u957f\u8fbe6\u4e2a\u5468\u671f\uff09\uff0c\u968f\u540e\u63a5\u53d7\u66ff\u96f7\u5229\u73e0\u5355\u6297\u5355\u836f\u7ef4\u6301\u6cbb\u7597\u6216\u5b89\u6170\u5242\u6cbb\u7597\uff0c\u76f4\u81f3\u75be\u75c5\u8fdb\u5c55\u6216\u51fa\u73b0\u4e0d\u53ef\u8010\u53d7\u7684\u6bd2\u6027\u3002<a href=\"https:\/\/oncologypro.esmo.org\/meeting-resources\/esmo-immuno-oncology-congress\/rationale-309-a-randomized-global-double-blind-phase-3-trial-of-tislelizumab-tis-vs-placebo-plus-gemcitabine-cisplatin-gp-as-1l-treatme\">\u4e2d\u671f\u5206\u6790<\/a>\uff08\u4e2d\u4f4d\u968f\u8bbf\u65f6\u95f4\u4e3a10\u4e2a\u6708\uff09\u65f6\uff0c\u8fbe\u5230\u4e86\u4e3b\u8981\u7ec8\u70b9\uff0c\u6839\u636e\u72ec\u7acb\u5ba1\u67e5\u59d4\u5458\u4f1a\uff08IRC\uff09\u7684\u8bc4\u4f30\uff0c\u66ff\u96f7\u5229\u73e0\u5355\u6297\u8054\u5408\u5316\u7597\u7ec4\u7684\u4e2d\u4f4dPFS\u4e3a9.2\u4e2a\u6708\uff0c\u800c\u5b89\u6170\u5242\u8054\u5408\u5316\u7597\u7ec4\u4e3a7.4\u4e2a\u6708\uff08\u98ce\u9669\u6bd4[HR]=0.52\uff0cP &lt; 0.0001\uff09\u3002\u4e2d\u4f4d\u968f\u8bbf15.5\u4e2a\u6708\u65f6\u7684\u66f4\u65b0\u5206\u6790\u663e\u793a\uff0c\u66ff\u96f7\u5229\u73e0\u5355\u6297\u8054\u5408\u5316\u7597\u7ec4\u7684\u4e2d\u4f4dPFS\u83b7\u76ca\u4e00\u81f4\uff089.6 vs. 7.4\u4e2a\u6708\uff0cHR=0.50\uff09\u3002\u5c3d\u7ba1\u672c\u5206\u6790\u65f6\u4ea4\u53c9\u7387\u7ea6\u4e3a40%\uff0c\u4e14\u603b\u751f\u5b58\u671f\uff08OS\uff09\u6570\u636e\u5c1a\u4e0d\u6210\u719f\uff0c\u4f46\u66ff\u96f7\u5229\u73e0\u5355\u6297\u8054\u5408\u5316\u7597\u663e\u793a\u4e86\u6709\u5229\u7684OS\u83b7\u76ca\uff08\u672a\u8fbe\u5230 [NR] vs. 23\u4e2a\u6708\uff0cHR=0.60\uff09\u3002\u6b64\u5916\uff0c\u66ff\u96f7\u5229\u73e0\u5355\u6297\u8054\u5408\u5316\u7597\u663e\u793a\u4e2d\u4f4dPFS2\uff08\u540e\u7eed\u6cbb\u7597\u540ePFS\uff09\u663e\u8457\u6539\u5584\uff08NR vs. 13.9\u4e2a\uff0cHR=0.38\uff09\u3002<\/p>\n\n\n\n<p>\u6839\u636e\u8be5\u62a5\u544a\uff0c\u65e0\u8bbaPD-L1\u8868\u8fbe\u5982\u4f55\uff0c\u5747\u89c2\u5bdf\u5230PFS\u83b7\u76ca\u3002\u7136\u800c\uff0c\u57fa\u56e0\u8868\u8fbe\u8c31\u7ed3\u679c\u8868\u660e\uff0c\u5177\u6709\u201c\u70ed\u201d\u80bf\u7624\u5fae\u73af\u5883\uff08\u4ee5\u514d\u75ab\u7ec6\u80de\u9ad8\u8868\u8fbe\u4e3a\u7279\u5f81\uff09\u7684\u60a3\u8005\u53ef\u80fd\u83b7\u5f97\u6700\u5927\u7684PFS\u83b7\u76ca\u3002\u66ff\u96f7\u5229\u73e0\u5355\u6297\u8054\u5408\u5316\u7597\u7684\u5b89\u5168\u6027\u7279\u5f81\u4e0e\u65e2\u5f80\u7ecf\u9a8c\u4e00\u81f4\uff0c\u672a\u53d1\u73b0\u65b0\u7684\u5b89\u5168\u6027\u4fe1\u53f7\u3002\u57fa\u4e8e\u8be5\u5206\u6790\u7684\u7ed3\u679c\uff0c\u5f20\u6559\u6388\u5f97\u51fa\u7ed3\u8bba\uff0c\u66ff\u96f7\u5229\u73e0\u5355\u6297\u8054\u5408\u5316\u7597\u53ef\u80fd\u6210\u4e3aR\/M NPC\u60a3\u8005\u7684\u4e00\u7ebf\u6807\u51c6\u6cbb\u7597\u3002Robert Haddad\u535a\u58eb\uff08\u7f8e\u56fd\u6ce2\u58eb\u987fDana-Farber\u764c\u75c7\u7814\u7a76\u6240\uff09\u5728\u4ed6\u5bf9\u8be5\u7814\u7a76\u7684\u7cbe\u5f69\u8ba8\u8bba\u4e2d\u79f0\u8d5e\u4e86RATIONALE-309\u7814\u7a76\uff0c\u6307\u51fa\u8fd9\u662f\u6bd4\u8f83PD-1\u6291\u5236\u5242\u8054\u5408\u5316\u7597\u4e0e\u6807\u51c6\u5316\u7597\u4f5c\u4e3a\u665a\u671fNPC\u4e00\u7ebf\u6cbb\u7597\u7684\u7b2c\u4e09\u9879III\u671f\u8bd5\u9a8c\u3002\u4e4b\u524d\uff0c<a href=\"https:\/\/www.nature.com\/articles\/s41591-021-01444-0\">JUPITER-02<\/a>\u7814\u7a76\u8bc4\u4f30\u4e86\u7279\u745e\u666e\u5229\u5355\u6297\uff0c\u800c<a href=\"https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(21)00302-8\/fulltext\">CAPTAIN-1st<\/a>\u7814\u7a76\u8bc4\u4ef7\u4e86\u5361\u745e\u5229\u73e0\u5355\u6297\u3002\u8fd9\u4e9b\u91cd\u8981\u8bd5\u9a8c\u4e2d\u7684\u6240\u6709\u4e09\u79cdPD-1\u6291\u5236\u5242\u5747\u5bfc\u81f4PFS\u7a33\u5065\u6539\u5584\uff0cHR\u8303\u56f4\u4e3a0.50\u81f30.54\u3002\u4ed6\u8fd8\u6307\u51fa\uff0c\u57fa\u4e8e\u8fd9\u4e9b\u7ed3\u679c\uff0cNCCN\u6700\u8fd1\u8c03\u6574\u5934\u9888\u764c\u6307\u5357\uff0c\u5c06\u5409\u897f\u4ed6\u6ee8-\u987a\u94c2\u8054\u5408PD-1\u6291\u5236\u5242\u4f5c\u4e3a\u665a\u671fNPC\u4e00\u7ebf\u6cbb\u7597\u7684\u201c\u5176\u4ed6\u63a8\u8350\u65b9\u6848\u201d\u4e4b\u4e00\u3002\u7136\u800c\uff0c\u7531\u4e8eNPC\u7814\u7a76\u4e2d\u4f7f\u7528\u7684\u4e09\u79cdPD-1\u6291\u5236\u5242\u5728\u7f8e\u56fd\u5747\u4e0d\u53ef\u53ca\uff0cNCCN\u76ee\u524d\u5efa\u8bae\u8054\u5408\u5e15\u535a\u5229\u73e0\u5355\u6297\u6216\u7eb3\u6b66\u5229\u5c24\u5355\u6297\u6cbb\u7597\u3002<\/p>\n\n\n\n<p><strong>\u53c2\u8003\u6587\u732e\uff1a<\/strong><br>Zhang L, et al. <em>J Clin Oncol<\/em>. 2022;40 (no.36_suppl); Abstract 384950.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u9f3b\u54bd\u764c\uff08Nasopharyngeal cancer\uff0cNPC\uff09\u5728\u897f\u65b9\u56fd\u5bb6\u662f\u4e00\u79cd\u7f55\u89c1\u75c5\uff0c\u800c\u5728\u4e1c\u5357\u4e9a\u53d1\u75c5\u7387\u8f83\u9ad8\u3002\u5927\u591a [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":3690,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[41],"tags":[],"class_list":["post-3701","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-41"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>PD-1\u6291\u5236\u5242\u8054\u5408\u5316\u7597\u83b7\u5f97\u665a\u671f\u9f3b\u54bd\u764c\u4e00\u7ebf\u6cbb\u7597\u8bc1\u636e - ACE Oncology<\/title>\n<meta name=\"description\" content=\"\u66ff\u96f7\u5229\u73e0\u5355\u6297\uff0c\u7b2c\u4e09\u4e2a\u88ab\u8bc1\u5b9e\u8054\u5408\u5316\u7597\u663e\u8457\u6539\u5584\u665a\u671fNPC\u60a3\u8005\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u7684PD-1\u6291\u5236\u5242\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PD-1\u6291\u5236\u5242\u8054\u5408\u5316\u7597\u83b7\u5f97\u665a\u671f\u9f3b\u54bd\u764c\u4e00\u7ebf\u6cbb\u7597\u8bc1\u636e - ACE Oncology\" \/>\n<meta property=\"og:description\" content=\"\u66ff\u96f7\u5229\u73e0\u5355\u6297\uff0c\u7b2c\u4e09\u4e2a\u88ab\u8bc1\u5b9e\u8054\u5408\u5316\u7597\u663e\u8457\u6539\u5584\u665a\u671fNPC\u60a3\u8005\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u7684PD-1\u6291\u5236\u5242\" \/>\n<meta property=\"og:url\" content=\"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/\" \/>\n<meta property=\"og:site_name\" content=\"ACE Oncology\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-05T05:43:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-05T05:43:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Blog-Picture-85-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"ACE Demo\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:site\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ACE Demo\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/\"},\"author\":{\"name\":\"ACE Demo\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0\"},\"headline\":\"PD-1\u6291\u5236\u5242\u8054\u5408\u5316\u7597\u83b7\u5f97\u665a\u671f\u9f3b\u54bd\u764c\u4e00\u7ebf\u6cbb\u7597\u8bc1\u636e\",\"datePublished\":\"2022-05-05T05:43:22+00:00\",\"dateModified\":\"2022-05-05T05:43:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/\"},\"wordCount\":68,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Blog-Picture-85-scaled.jpg\",\"articleSection\":[\"\u4f1a\u8bae\u52a8\u6001\"],\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/\",\"url\":\"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/\",\"name\":\"PD-1\u6291\u5236\u5242\u8054\u5408\u5316\u7597\u83b7\u5f97\u665a\u671f\u9f3b\u54bd\u764c\u4e00\u7ebf\u6cbb\u7597\u8bc1\u636e - ACE Oncology\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Blog-Picture-85-scaled.jpg\",\"datePublished\":\"2022-05-05T05:43:22+00:00\",\"dateModified\":\"2022-05-05T05:43:23+00:00\",\"description\":\"\u66ff\u96f7\u5229\u73e0\u5355\u6297\uff0c\u7b2c\u4e09\u4e2a\u88ab\u8bc1\u5b9e\u8054\u5408\u5316\u7597\u663e\u8457\u6539\u5584\u665a\u671fNPC\u60a3\u8005\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u7684PD-1\u6291\u5236\u5242\",\"breadcrumb\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/#primaryimage\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Blog-Picture-85-scaled.jpg\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Blog-Picture-85-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"ACE Oncology\",\"item\":\"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PD-1\u6291\u5236\u5242\u8054\u5408\u5316\u7597\u83b7\u5f97\u665a\u671f\u9f3b\u54bd\u764c\u4e00\u7ebf\u6cbb\u7597\u8bc1\u636e\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/aceoncology.org\/#website\",\"url\":\"https:\/\/aceoncology.org\/\",\"name\":\"ACE Oncology\",\"description\":\"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.\",\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/aceoncology.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/aceoncology.org\/#organization\",\"name\":\"ACE Oncology\",\"url\":\"https:\/\/aceoncology.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"width\":156,\"height\":83,\"caption\":\"ACE Oncology\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/ace_oncology\",\"https:\/\/www.linkedin.com\/company\/aceoncology\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0\",\"name\":\"ACE Demo\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g\",\"caption\":\"ACE Demo\"},\"url\":\"https:\/\/aceoncology.org\/zh-hans\/author\/demo\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PD-1\u6291\u5236\u5242\u8054\u5408\u5316\u7597\u83b7\u5f97\u665a\u671f\u9f3b\u54bd\u764c\u4e00\u7ebf\u6cbb\u7597\u8bc1\u636e - ACE Oncology","description":"\u66ff\u96f7\u5229\u73e0\u5355\u6297\uff0c\u7b2c\u4e09\u4e2a\u88ab\u8bc1\u5b9e\u8054\u5408\u5316\u7597\u663e\u8457\u6539\u5584\u665a\u671fNPC\u60a3\u8005\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u7684PD-1\u6291\u5236\u5242","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/","og_locale":"zh_CN","og_type":"article","og_title":"PD-1\u6291\u5236\u5242\u8054\u5408\u5316\u7597\u83b7\u5f97\u665a\u671f\u9f3b\u54bd\u764c\u4e00\u7ebf\u6cbb\u7597\u8bc1\u636e - ACE Oncology","og_description":"\u66ff\u96f7\u5229\u73e0\u5355\u6297\uff0c\u7b2c\u4e09\u4e2a\u88ab\u8bc1\u5b9e\u8054\u5408\u5316\u7597\u663e\u8457\u6539\u5584\u665a\u671fNPC\u60a3\u8005\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u7684PD-1\u6291\u5236\u5242","og_url":"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/","og_site_name":"ACE Oncology","article_published_time":"2022-05-05T05:43:22+00:00","article_modified_time":"2022-05-05T05:43:23+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Blog-Picture-85-scaled.jpg","type":"image\/jpeg"}],"author":"ACE Demo","twitter_card":"summary_large_image","twitter_creator":"@ace_oncology","twitter_site":"@ace_oncology","twitter_misc":{"\u4f5c\u8005":"ACE Demo","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"1 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/#article","isPartOf":{"@id":"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/"},"author":{"name":"ACE Demo","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0"},"headline":"PD-1\u6291\u5236\u5242\u8054\u5408\u5316\u7597\u83b7\u5f97\u665a\u671f\u9f3b\u54bd\u764c\u4e00\u7ebf\u6cbb\u7597\u8bc1\u636e","datePublished":"2022-05-05T05:43:22+00:00","dateModified":"2022-05-05T05:43:23+00:00","mainEntityOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/"},"wordCount":68,"commentCount":0,"publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Blog-Picture-85-scaled.jpg","articleSection":["\u4f1a\u8bae\u52a8\u6001"],"inLanguage":"zh-Hans","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/","url":"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/","name":"PD-1\u6291\u5236\u5242\u8054\u5408\u5316\u7597\u83b7\u5f97\u665a\u671f\u9f3b\u54bd\u764c\u4e00\u7ebf\u6cbb\u7597\u8bc1\u636e - ACE Oncology","isPartOf":{"@id":"https:\/\/aceoncology.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/#primaryimage"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Blog-Picture-85-scaled.jpg","datePublished":"2022-05-05T05:43:22+00:00","dateModified":"2022-05-05T05:43:23+00:00","description":"\u66ff\u96f7\u5229\u73e0\u5355\u6297\uff0c\u7b2c\u4e09\u4e2a\u88ab\u8bc1\u5b9e\u8054\u5408\u5316\u7597\u663e\u8457\u6539\u5584\u665a\u671fNPC\u60a3\u8005\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u7684PD-1\u6291\u5236\u5242","breadcrumb":{"@id":"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/#primaryimage","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Blog-Picture-85-scaled.jpg","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/04\/Blog-Picture-85-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/aceoncology.org\/zh-hans\/tislelizumab-plus-chemo-regimen-in-npc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"ACE Oncology","item":"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/"},{"@type":"ListItem","position":2,"name":"PD-1\u6291\u5236\u5242\u8054\u5408\u5316\u7597\u83b7\u5f97\u665a\u671f\u9f3b\u54bd\u764c\u4e00\u7ebf\u6cbb\u7597\u8bc1\u636e"}]},{"@type":"WebSite","@id":"https:\/\/aceoncology.org\/#website","url":"https:\/\/aceoncology.org\/","name":"ACE Oncology","description":"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.","publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/aceoncology.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/aceoncology.org\/#organization","name":"ACE Oncology","url":"https:\/\/aceoncology.org\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","width":156,"height":83,"caption":"ACE Oncology"},"image":{"@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ace_oncology","https:\/\/www.linkedin.com\/company\/aceoncology"]},{"@type":"Person","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/b551dd0a4b75a5b349e0a71560a8b3c0","name":"ACE Demo","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5364d75bb683367c9b56b8d9914df888527c9d170b78bbc5ef94bb01125a2253?s=96&d=mm&r=g","caption":"ACE Demo"},"url":"https:\/\/aceoncology.org\/zh-hans\/author\/demo\/"}]}},"_links":{"self":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/3701","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/comments?post=3701"}],"version-history":[{"count":1,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/3701\/revisions"}],"predecessor-version":[{"id":3702,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/3701\/revisions\/3702"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media\/3690"}],"wp:attachment":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media?parent=3701"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/categories?post=3701"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/tags?post=3701"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}